About: Gilles Freyer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Gilles Freyer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

French professor, oncologist and medical professional

Attributes	Values
rdf:type	Item
description	French professor, oncologist and medical professional (en)
rdfs:label	Gilles Freyer (en) Gilles Freyer (nl)
skos:prefLabel	Gilles Freyer (en) Gilles Freyer (nl)
name	Gilles Freyer (en) Gilles Freyer (nl)
given name	wds:Q79780278-F0C041D9-84CC-40F8-8E5C-A4B40384133B
given name	Gilles
instance of	wds:Q79780278-6c6dc19e-44ab-b590-a2c4-f92b98764e82
instance of	Homo sapiens
Google Knowledge Graph ID	wds:Q79780278-B2ACE36A-6F5B-4550-ADB3-67906009768E
Google Knowledge Graph ID	http://g.co/kg/g/11f3pq7mxm
Google Knowledge Graph ID	/g/11f3pq7mxm
Google Scholar author ID	wds:Q79780278-D33C1679-DB5A-41DA-8302-35915E33931E
Google Scholar author ID	MCVyX1gAAAAJ
sex or gender	wds:Q79780278-6d71975e-4d20-06e0-b418-0701d4949a2f
VIAF ID	wds:Q79780278-22818EC1-BDF5-4C3A-B6DE-FD12783AD1ED
Bibliothèque nationale de France ID	wds:Q79780278-f38c5c03-47f6-7282-dd0c-2c0affeaf947
IdRef ID	wds:Q79780278-00497583-4fcd-8145-043b-ce77660b34bc
National Library of Israel J9U ID	wds:Q79780278-405C69CB-D81D-4A4E-B643-50D131ABE54F
VIAF ID	http://viaf.org/viaf/17442808
Bibliothèque nationale de France ID	http://data.bnf.fr/ark:/12148/cb144410819#about
IdRef ID	http://www.idref.fr/058560688/id
sex or gender	male
VIAF ID	17442808
Bibliothèque nationale de France ID	144410819
IdRef ID	058560688
National Library of Israel J9U ID	987007364841005171
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q79780278 Gilles Freyer
is author of	EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Optimal management of breast cancer in the elderly patient: current perspectives Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial. Chemotherapy may be delivered based on an integrated view of tumour dynamics. Biology of cancer and aging: a complex association with cellular senescence. Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment Routine Clinical Practice for Patients With Recurrent Ovarian Carcinoma: Results From the TROCADERO Study Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. Agreement for depression diagnosis between DSM-IV-TR criteria, three validated scales, oncologist assessment, and psychiatric clinical interview in elderly patients with advanced ovarian cancer Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. A dynamic model of hand-and-foot syndrome in patients receiving capecitabine Inclusion of elderly patients in oncology clinical trials. Oral vinorelbine: feasibility and safety profile. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS). Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs Improving cancer patient care with combined medication error reviews and morbidity and mortality conferences EPICC study: evaluation of pharmaceutical intervention in cancer care Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: a multicentric pilot-evaluation. Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French survey Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7) [Metastatic prostate cancer treatment in the elderly] Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials Changes in the Use of Comprehensive Geriatric Assessment in Clinical Trials for Older Patients with Cancer over Time [Is geriatric assessment adapted to radiotherapy?] Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial [Node negative breast cancer. Beyond international consensus: a pragmatic approach] Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: Results of a pooled analysis of three GINECO phase II trials Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) [Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]. Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice Les enjeux de l’observance pour les nouvelles chimiothérapies par voie orale : intérêt du modèle pharmacocinétique-pharmacodynamique [Primary peritoneal tumors: report on a series of eight cases and review of the literature] [Pharmacology of anticancer drugs in the elderly: tools for dose-adjustment] Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software